Literature DB >> 2850290

Decreased cardiac response to isoproterenol infusion in acute and chronic hypoxia.

J P Richalet1, P Larmignat, C Rathat, A Kéromès, P Baud, F Lhoste.   

Abstract

The hypothesis of a blunted chronotropic response of cardiac beta-adrenergic receptors in altitude hypoxia was tested in nine subjects at sea level (SL) by infusion of isoproterenol. Observations were made at SL, in acute hypoxia (2 days at 4,350 m, condition H1), in more prolonged hypoxia [13 days between 850 and 4,800 m, condition H2] and in chronic hypoxia [21 days at 4,800 m, condition H3]. Resting heart rate was higher in all hypoxic conditions. Resting norepinephrine concentrations were found to be significantly higher in conditions H2 (1.64 +/- 0.59) and H3 (1.74 +/- 0.76) than at SL (0.77 +/- 0.18 ng/ml). Isoproterenol, diluted in saline, was infused at increasing doses of 0.0, 0.02, 0.04, and 0.06 micrograms.kg-1.min-1. For the highest dose, there was a significantly smaller increase in heart rate in conditions H1 (35 +/- 9), H2 (33 +/- 11), and H3 (31 +/- 11) than at SL (45 +/- 8 min-1). The increase in pulse (systolic/diastolic) pressure, considered as the vascular response to isoproterenol infusion, was smaller in condition H3 (29 +/- 16) than at SL (51 +/- 24 mmHg). There was a significant increase in the dose of isoproterenol required to increase heart rate by 25 min-1 and decrease in slope of heart rate increase vs. log(dose) relationship in conditions H2 and H3. Thus an hypoxia-related attenuated response of beta-adrenergic receptors to exogenous stimulation was found in humans.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2850290     DOI: 10.1152/jappl.1988.65.5.1957

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  24 in total

1.  Second generation Tibetan lowlanders acclimatize to high altitude more quickly than Caucasians.

Authors:  Claudio Marconi; Mauro Marzorati; Bruno Grassi; Buddha Basnyat; Angelo Colombini; Bengt Kayser; Paolo Cerretelli
Journal:  J Physiol       Date:  2004-02-06       Impact factor: 5.182

2.  Changes in structure and function of the human left ventricle after acclimatization to high altitude.

Authors:  R Scognamiglio; A Ponchia; G Fasoli; G Miraglia
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1991

Review 3.  Physiological responses to exercise at altitude : an update.

Authors:  Robert S Mazzeo
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

4.  Saliva flow and composition in humans exposed to acute altitude hypoxia.

Authors:  P Pilardeau; J P Richalet; P Bouissou; J Vaysse; P Larmignat; A Boom
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1990

5.  Blood pressure changes in young male subjects exposed to a median altitude.

Authors:  Ali Sizlan; Recai Ogur; Mustafa Ozer; M Kemal Irmak
Journal:  Clin Auton Res       Date:  2008-04       Impact factor: 4.435

6.  Effects of high altitude acclimatization on heart rate variability in resting humans.

Authors:  R Perini; S Milesi; L Biancardi; A Veicsteinas
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

7.  Benefits of training at moderate altitude versus sea level training in amateur runners.

Authors:  M Burtscher; W Nachbauer; P Baumgartl; M Philadelphy
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1996

8.  The application of maximal heart rate predictive equations in hypoxic conditions.

Authors:  Carla A Gallagher; Mark E T Willems; Mark P Lewis; Stephen D Myers
Journal:  Eur J Appl Physiol       Date:  2014-10-08       Impact factor: 3.078

9.  The effect of sucrose ingestion on autonomic nervous system function in young subjects during acute moderate hypoxia.

Authors:  Matjaz Klemenc; Jerica Maver; Tanja Princi; Polona Flander; Petra Golja
Journal:  Eur J Appl Physiol       Date:  2008-07-26       Impact factor: 3.078

10.  Chronic hypoxia increases blood pressure and noradrenaline spillover in healthy humans.

Authors:  Jose A L Calbet
Journal:  J Physiol       Date:  2003-07-04       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.